Apremilast is effective in controlling the progression of adult vitiligo: A case series

Majid, Imran; Imran, Saher; Batool, Sameena

doi:10.1111/dth.12923

Cited by 24 publications

(29 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study by Majid, Imran, and Batool (), 13 patients who had not responded to systemic therapy were treated with systemic apremilast; a 61.5% repigmentation rate was achieved after 3 months. However, treatment was stopped after two patients developed headache and severe gastrointestinal complaints.…”

Section: Discussionmentioning

confidence: 99%

“…In a study by Majid, Imran, and Batool (2019), 13 patients who had not responded to systemic therapy were treated with systemic apremilast; a 61.5% repigmentation rate was achieved after 3 months.…”

Section: Discussionmentioning

confidence: 99%

“…However, treatment was stopped after two patients developed headache and severe gastrointestinal complaints. These side effects are the main barriers to the wider use of this drug (Majid et al, ).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Effectiveness of topicalNigella sativafor vitiligo treatment

Saraç

Kapıcıoğlu

Şener

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

Vitiligo is a pigment disease characterized by the disruption of melanocyte structure and function. Its etiology is unknown; however, genetic predisposition, biochemical factors, and neural mechanisms are thought to be effective. Although many agents are being used for its treatment, generally there is no absolute cure. The aim of the present study is to evaluate the effectiveness of topical Nigella sativa seed oil on vitiligo patients. Thirty‐three vitiligo patients were included in the study. Totally 47 areas were evaluated in all patients. Cream containing N sativa seed oil was topically applied to hands, face, and genital region two times a day for 6 months. Statistically significant repigmentation was detected in hands, face, and genital region, the three treatment areas, and the p values are found .005, .001, and .004, respectively. N sativa can be used as an adjuvant therapy that can contribute to the treatment especially in sensitive skin areas like genital region.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effectiveness of topicalNigella sativafor vitiligo treatment

Saraç

Kapıcıoğlu

Şener

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…62,63 A case series of 13 patients found 61.5% achieved at least partial repigmentation (with as needed topical tacrolimus) and a 7.1% reduction in VASI. 64 Additional case reports have found improvement in both recalcitrant acral and generalized vitiligo without lasting or serious TEAEs. 65,66 Case series and reports detailing efficacy of apremilast for off-label dermatoses Palmoplantar pustulosis Although once considered a subtype of palmoplantar psoriasis, beginning in 2007 palmoplantar pustulosis has been deigned its own entity.…”

Section: Rosaceamentioning

confidence: 99%

Apremilast as an Off-Label Therapeutic Agent

Marson

Lebwohl

2021

J of Skin

View full text Add to dashboard Cite

Objective: To review the literature regarding the efficacy and safety of off-label use of apremilast in combination therapies for psoriasis and psoriatic arthritis and for other currently off-label inflammatory dermatoses. Methods: The Medline database was queried for all relevant articles published between 2014 and 2021 using exploded MeSH terms and keywords pertaining to the following themes: off-label, combination therapy, biologics, biologic therapy, methotrexate, and systemic psoriasis therapy. The Boolean term “AND” was used to find the intersection of these themes with the term “apremilast.” Results: 8 case series and 6 case reports investigated the use of apremilast in combination therapy for psoriasis and psoriatic arthritis. Addition of apremilast improved PASI scores by 31.8-77.4% among case series and 80-100% among case reports with adverse effects primarily consisting of gastrointestinal symptoms. 5 randomized-control trials (RCT), 9 open-label trials, 18 case series, and 30 case reports investigated the use of apremilast for off-label dermatoses. In RCTs, apremilast showed potential efficacy for atopic dermatitis and hidradenitis suppurativa. Open-label trials found apremilast efficacious for atopic dermatitis, allergic contact dermatitis, chronic pruritus, cutaneous sarcoidosis, discoid lupus erythematosus, hidradenitis suppurativa, lichen planus, prurigo nodularis, rosacea, and vitiligo. Limitations: Small sample size and short follow duration up for available randomized-control and open-label trials. Current data from case series/reports potentially limits generalizability of findings. Conclusion: Apremilast's safety profile makes it a potential efficacious, non-biologic systemic agent for monotherapy and combination therapy for a wide range of inflammatory dermatoses.

show abstract

“…A case series by Majid et al recently showed the ability of apremilast to reduce progression and induce repigmentation of vitiligo lesions. 21 While no clinical studies are yet available for crisaborole, a short communication from Tausend et al provides some evidence of the potential effectiveness of crisaborole for the treatment of vitiligo. 22 In their report, a 40-year-old male with a 20-year history of persistent vitiligo on the ears was given crisaborole 2% ointment with instructions for twice daily application.…”

Section: Vitiligomentioning

confidence: 99%

Off-Label Therapeutic Potential of Crisaborole

2020

View full text Add to dashboard Cite

Crisaborole, a topical phosphodiesterase-4 inhibitor, was recently approved in 2016 for the treatment of mild to moderate atopic dermatitis in adults and children greater than 2 years of age. Since that time, several case reports and a small randomized controlled trial have been published regarding the off-label use of crisaborole for the treatment of other inflammatory dermatologic disorders. This paper reviews the current, albeit limited, evidence for off-label use of crisaborole for psoriasis, seborrheic dermatitis, vitiligo, and inflammatory linear verrucous epidermal nevus. Additional potential therapeutic uses for crisaborole are also postulated, based on its mechanism of action. Future studies are required to elucidate the full therapeutic potential of crisaborole; however, it is a welcome addition to the current nonsteroid topical treatments for inflammatory dermatologic disease.

show abstract

Apremilast is effective in controlling the progression of adult vitiligo: A case series

Cited by 24 publications

References 9 publications

Effectiveness of topicalNigella sativafor vitiligo treatment

Effectiveness of topicalNigella sativafor vitiligo treatment

Apremilast as an Off-Label Therapeutic Agent

Off-Label Therapeutic Potential of Crisaborole

Contact Info

Product

Resources

About